Observational studyFrontiers in endocrinology2026
Clinical and metabolic factors associated with response to postoperative radioactive iodine therapy in Chinese obese patients with papillary thyroid carcinoma.
Observational study in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objective: Obesity is a heterogeneous metabolic condition that may influence tumor biology and therapeutic outcomes. However, factors associated with the response to postoperative radioactive iodine ( Methods: This retrospective observational study included obese patients with PTC who underwent postoperative Results: A total of 219 obese patients with PTC were included, with a median follow-up of 31.00 months. At the last follow-up, 91 patients (41.6%) achieved ER. In multivariable analysis, higher high-density lipoprotein (HDL) levels were independently associated with an increased likelihood of ER (OR = 22.891, 95% CI: 2.644-198.206, P = 0.004), whereas higher pre-ablation stimulated thyroglobulin (sTg) levels were independently associated with a lower likelihood of ER (OR = 0.793, 95% CI: 0.719-0.876, P < 0.001). Triglycerides (TG) also showed a weaker association with treatment response (OR = 0.662, 95% CI: 0.442-0.991, P = 0.045). Among the individual indicators, sTg showed the best discriminatory performance (AUC = 0.767), followed by HDL (AUC = 0.672) and TG (AUC = 0.624). A combined model incorporating HDL and sTg improved predictive performance (AUC = 0.822). Conclusion: In obese patients with PTC who underwent postoperative
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.